Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET
Company Participants
Joshua Higa - Head of Investor Relations
Emil Kakkis - Founder, President and Chief Executive Officer
Erik Harris - Executive Vice President and Chief Commercial Officer
Camille Bedrosian - Executive Vice President and Chief Medical Officer
Aaron Olson - SVP, Corporate Strategy and Finance
Ted Hazinga - Chief Accounting Officer
Conference Call Participants
Gena Wang - Barclays
Chris Raymond - Piper Sandler
Joon Lee - Truist Securities
Yigal Nochomovitz - Citi Research
Tazeen Ahmad - Bank of America
Jeff Hung - Morgan Stanley
Maury Raycroft - Jefferies LLC
Dae Gon Ha - Stifel
Liisa Bayko - Evercore
Anupam Rama - JPMorgan
Joel Beatty - R W. Baird
Operator
Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2022 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call over to Joshua Higa, Executive Director and Head of Investor Relations.
Joshua Higa
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Camille Bedrosian, Chief Medical Officer; Aaron Olson, Senior Vice President of Corporate Strategy and Finance; and Ted Hazinga, Chief Accounting Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call over to Emil.
Emil Kakkis
Thanks, Josh, and good afternoon, everyone. Some of you may have listened in on my presentation at the recent JPMorgan Healthcare Conference where I talked about our focus for areas for 2023. Over last year, we completed several strategic investments, aligned our teams and resources around the highest value-generating programs for the company. This year, we'll continue to focus on operational efficiency while generating data from our key clinical programs in Angelman, osteogenesis imperfecta and our pivotal gene therapy studies.
In 2022, we generated more than $350 million of global revenue in our fifth year as a commercial company. This year, we expect revenue to be in the $420 million to $450 million range from our four products across five indications. We expect a steady revenue growth to continue as the existing products are still in relatively early phases of commercialization.